EUVIMEDDescoperă EUVIMED
Open access · CC BY-NC-ND 4.0

Monte Carlo‐based dosimetry of proposed bi‐radionuclide ( 125 I and 106 Ru/ 106 Rh) eye plaque: A feasibility study

Subhalaxmi Mishra, T Palani Selvam, Sridhar Sahoo, Sanjay Kumar Saxena, Yogendra Kumar, Balvinder K Sapra

Medical Physics · 2024

DOI: 10.1002/mp.17257 ↗

At a glance

Journal article in Medical Physics, 2024. Written by Subhalaxmi Mishra and 5 co-authors. Institution: Radiological Physics and Advisory Division, Health, Safety & Environment Group, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India. Major MEDLINE topics: Monte Carlo Method, Brachytherapy, Iodine Radioisotopes, Feasibility Studies. Cited 1 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

Combining the sharp dose fall off feature of beta‐emitting 106 Ru/ 106 Rh radionuclide with larger penetration depth feature of photon‐emitting 125 I radionuclide in a bi‐radionuclide plaque, prescribed dose to the tumor apex can be delivered while maintaining the tumor dose uniformity and sparing the organs at risk. The potential advantages of bi‐radionuclide plaque could be of interest in context of ocular brachytherapy.

Purpose

The aim of the study is to evaluate the dosimetric advantages of a proposed bi‐radionuclide plaque for two different designs, consisting of indigenous 125 I seeds and 106 Ru/ 106 Rh plaque, using Monte Carlo technique. The study also explores the influence of other commercial 125 I seed models and presence or absence of silastic/acrylic seed carrier on the calculated dose distributions. The study further included the calculation of depth dose distributions for the bi‐radionuclide eye plaque for which experimental data are available.

Methods

The proposed bi‐radionuclide plaque consists of a 1.2‐mm‐thick silver (Ag) spherical shell with radius of curvature of 12.5 mm, 20 µm‐thick‐ 106 Ru/ 106 Rh encapsulated between 0.2 mm Ag disk, and a 0.1‐mm‐thick Ag window, and water‐equivalent gel containing 12 symmetrically arranged 125 I seeds. Two bi‐radionuclide plaque models investigated in the present study are designated as Design I and Design II. In Design I, 125 I seeds are placed on the top of the plaque, while in Design II 106 Ru/ 106 Rh source is positioned on the top of the plaque. In Monte Carlo calculations, the plaque is positioned in a spherical water phantom of 30 cm diameter.

Results

The proposed bi‐radionuclide eye plaque demonstrated superior dose distributions as compared to 125 I or 106 Ru plaque for tumor thicknesses ranges from 5 to 10 mm. Amongst the designs, dose at a given voxel for Design I is higher as compared to the corresponding voxel dose for Design II. This difference is attributed to the higher degree of attenuation of 125 I photons in Ag as compared to beta particles. Influence of different 125 I seed models on the normalized lateral dose profiles of Design I (in the absence of carrier) is negligible and within 5% on the central axis depth dose distribution as compared to the corresponding values of the plaque that has indigenous 125 I seeds. In the presence of a silastic/acrylic seed carrier, the normalized central axis dose distributions of Design I are smaller by 3%–12% as compared to the corresponding values in the absence of a seed carrier. For the published bi‐radionuclide plaque model, good agreement is observed between the Monte Carlo‐calculated and published measured depth dose distributions for clinically relevant depths.

Conclusion

Regardless of the type of 125 I seed model utilized and whether silastic/acrylic seed carrier is present or not, Design I bi‐radionuclide plaque offers superior dose distributions in terms of tumor dose uniformity, rapid dose fall off and lesser dose to nearby critical organs at risk over the Design II plaque. This shows that Design I bi‐radionuclide plaque could be a promising alternative to 125 I plaque for treatment of tumor sizes in the range 5 to 10 mm.

Subjects

MeSH terms (MEDLINE)

Monte Carlo MethodBrachytherapyIodine RadioisotopesFeasibility StudiesRadiometryHumansRadiotherapy DosageRuthenium RadioisotopesEyeEye Neoplasms

Author keywords

106Ru/106Rh radionuclide125I seedsMonte Carlobi‐radionuclide eye plaqueegs_brachy

Substances

Iodine-125Iodine RadioisotopesRuthenium RadioisotopesRuthenium-106

Authors and institutions

  • Radiological Physics and Advisory Division, Health, Safety & Environment Group, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.
  • Homi Bhabha National Institute, Anushaktinagar, Mumbai, Maharashtra, India.
  • Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.

Cite

APA

Mishra, S., Selvam, T. P., Sahoo, S., Saxena, S. K., Kumar, Y., & Sapra, B. K. (2024). Monte Carlo‐based dosimetry of proposed bi‐radionuclide ( 125 I and 106 Ru/ 106 Rh) eye plaque: A feasibility study. Medical Physics. https://doi.org/10.1002/mp.17257

Vancouver

Mishra S, Selvam TP, Sahoo S, Saxena SK, Kumar Y, Sapra BK. Monte Carlo‐based dosimetry of proposed bi‐radionuclide ( 125 I and 106 Ru/ 106 Rh) eye plaque: A feasibility study. Medical Physics. 2024. doi:10.1002/mp.17257

BibTeX
@article{Mishra2024,
  author = {Mishra, Subhalaxmi and Selvam, T Palani and Sahoo, Sridhar and Saxena, Sanjay Kumar and Kumar, Yogendra and Sapra, Balvinder K},
  title = {Monte Carlo‐based dosimetry of proposed bi‐radionuclide ( 125 I and 106 Ru/ 106 Rh) eye plaque: A feasibility study},
  journal = {Medical Physics},
  year = {2024},
  doi = {10.1002/mp.17257}
}
Start for free →